Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT01705730
- Locations
- 🇧🇪
CH EpiCURA Site Ath, Ath, Belgium
🇧🇪CHU Brugmann (Victor Horta), Bruxelles, Belgium
🇧🇪ASZ Aalst, Aalst, Belgium
A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 269
- Registration Number
- NCT01705704
A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT01705717
- Locations
- 🇹🇭
Faculty of Medicine Vajira Hospital; Division of Gastroenterology and Hepatology, Bangkok, Thailand
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
- Conditions
- Breast CancerGastric Cancer
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT01702558
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, PR, Brazil
🇧🇷Instituto Oncologico de Ribeirao Preto - INORP, Ribeirao Preto, SP, Brazil
🇧🇷Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*, Sao Jose do Rio Preto, SP, Brazil
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01702714
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2185
- Registration Number
- NCT01702571
- Locations
- 🇦🇺
Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia
🇦🇷CEMIC, Buenos Aires, Argentina
🇧🇪CHU Sart-Tilman, Liège, Belgium
A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01701739
A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
- Conditions
- Healthy Volunteer, Alzheimer's Disease
- Interventions
- Drug: 11C-L-deprenyl-D2
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT01701089
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01697436
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
- Conditions
- Hepatitis B, Chronic
- Interventions
- Other: Interleukin 28B testing
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT01697501
- Locations
- 🇮🇹
Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy
🇮🇹Azienda Ospedaliera Policlinico Consorziale di Bari; Clinica Malattie Infettive, Bari, Puglia, Italy
🇮🇹Uni Di Cagliari; Dept. Di Scienze Mediche, Cagliari, Sardegna, Italy